Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

KalVista raises £8mm through its Series A round; spins off from Vantia Therapeutics

Executive Summary

Vantia Therapeutics Ltd. has spun off KalVista Pharmaceuticals Ltd., a newly formed company co-founded with experts from Harvard Medical School that is focused on diabetic macular edema (DME). KalVista simultaneously raised £8mm ($13.2mm) through its Series A venture round to Novo AS and SV Life Sciences. (These were the two backers that supported the spin-off of Vantia from Ferring Pharmaceuticals AS about three years ago.)
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Private Placement

Related Companies